- Home
- AZN vs MRK Comparison
AZN vs MRK Comparison
Compare AZN & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZN | MRK |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United Kingdom | United States |
| Employees | 96100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.4B | 268.7B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | AZN | MRK |
|---|---|---|
| Price | $187.53 | $122.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 17 |
| Target Price | N/A | ★ $125.59 |
| AVG Volume (30 Days) | 1.8M | ★ 6.9M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | 1.73% | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $10.34 | $3.61 |
| Revenue Next Year | $6.43 | $5.41 |
| P/E Ratio | $31.91 | ★ N/A |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $68.62 | $75.40 |
| 52 Week High | $212.71 | $125.14 |
Technical Indicators
Market Signals| Indicator | AZN | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 67.63 |
| Support Level | $180.98 | $112.49 |
| Resistance Level | $208.61 | $124.57 |
| Average True Range (ATR) | 3.00 | 2.30 |
| MACD | 0.80 | 1.02 |
| Stochastic Oscillator | 66.00 | 97.31 |
Price Performance
Historical ComparisonAbout AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).